---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-003930"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T03:14:21.503732+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kymera reports Q4 2022 net loss $34.9M; cash $559.5M; Sanofi to start KT-474 Phase 2 in 2023

## Summary
- Net loss Q4 2022: $34.9M, full year $154.8M; cash and investments $559.5M as of Dec 31, 2022, runway into H2 2025.
- Collaboration revenue Q4 $16.1M, full year $46.8M; R&D expenses $43.1M Q4, $164.2M full year.
- Sanofi to initiate Phase 2 trial of KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis in 2023.
- Phase 1 trials for KT-333 (STAT3) and KT-413 (IRAKIMiD) ongoing; clinical activity data expected in 2023.
- KT-253 (MDM2) IND cleared; Phase 1 trial to start early 2023 in solid tumors and hematological malignancies.

## SEC filing metadata
- accession: 0000950170-23-003930
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000095017023003930/0000950170-23-003930-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000095017023003930/kymr-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-003930
- JSON: https://secwatch.observer/filing/0000950170-23-003930.json
- Plain text: https://secwatch.observer/filing/0000950170-23-003930.txt

## Key facts
- Earnings Releases
  Kymera Therapeutics, Inc. reported financial results for the quarter ended December 31, 2022.
  - Period: the quarter ended December 31, 2022
  - Result: reported results
  source text: On February 23, 2023, Kymera Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2022 and for the fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000095017023003930/0000950170-23-003930-index.htm
- Earnings Releases
  Kymera Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2022.
  - Period: the fiscal year ended December 31, 2022
  - Result: reported results
  source text: On February 23, 2023, Kymera Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2022 and for the fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000095017023003930/0000950170-23-003930-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.